Sarepta Therapeutics, Inc. or Evotec SE: Who Leads in Yearly Revenue?

Biotech Giants' Revenue Battle: 2014-2023

__timestampEvotec SESarepta Therapeutics, Inc.
Wednesday, January 1, 2014894960009757000
Thursday, January 1, 20151276770001253000
Friday, January 1, 20161645070005421000
Sunday, January 1, 2017257630000154584000
Monday, January 1, 2018375405000301034000
Tuesday, January 1, 2019446437000380833000
Wednesday, January 1, 2020500924000540099000
Friday, January 1, 2021618034000701887000
Saturday, January 1, 2022751448000933013000
Sunday, January 1, 20237814260001243336000
Loading chart...

Data in motion

A Tale of Two Biotechs: Revenue Race from 2014 to 2023

In the competitive world of biotechnology, revenue growth is a key indicator of success. Over the past decade, Sarepta Therapeutics, Inc. and Evotec SE have been neck and neck in their quest for financial dominance. Starting in 2014, Evotec SE led the race with a revenue of approximately $89 million, while Sarepta trailed with just under $10 million. However, the tables turned dramatically by 2023, with Sarepta's revenue surging to over $1.2 billion, a staggering increase of over 12,000%. Meanwhile, Evotec SE also experienced impressive growth, reaching nearly $781 million, marking an increase of over 770% from its 2014 figures. This remarkable growth trajectory highlights the dynamic nature of the biotech industry and the relentless pursuit of innovation and market expansion by these two companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025